Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCFA Proposes Cost As A Medicare Coverage Criteria If Alternatives Exist

Executive Summary

The Health Care Financing Administration would consider cost in deciding whether Medicare should cover a medical technology that employs the same "clinical modality" as an alternative treatment used for the same indication and already covered by Medicare.

You may also be interested in...



“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?

The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests

“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?

The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests

HCFA Cost Considerations In Proposed Drug Coverage Criteria To Be Revised

The Health Care Financing Administration plans to eliminate or significantly scale back the role of cost in its proposed criteria for making Medicare drug coverage decisions, the agency indicated after receiving comments on its May 16 notice of intent to publish a proposed rule.

Related Content

UsernamePublicRestriction

Register

PS036032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel